Lilly Takes Another Leap Into Gene Therapy With Jaguar
Co-leads $139m Fundraising
Following last year's licensing deal with Precision Biosciences and the acquisition of Prevail Therapeutics, Eli Lilly is expanding its gene therapy efforts by backing Jaguar, a start-up staffed by former AveXis bosses.
You may also be interested in...
With the planned $487m acquisition of sensorineural-focused Akouos, Lilly makes its second gene therapy M&A play in two years, on top of partnering/financing activity in the space.
CEO Dave Ricks told investors Lilly will succeed via volume-driven growth of nine key products launched since 2019, which its commitment to lower prices will facilitate.
The diuretic bumetanide had shown potential to improve the core symptoms of children and adolescents with autism in small studies but has failed to demonstrate any sign of effectiveness in two late-stage trials.